ArticleCancer reports (Hoboken, N.J.)2025
In Lower-Grade Gliomas, the SPARC Family Exacerbates Prognosis by Influencing Immunity, Stemness, and Metabolism.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SPARCL1 Enrichment at the Glioblastoma Invasive Front Is Consistent with Synaptogenic and Angiogenic Tumor Niches.International journal of molecular sciences · 2026Article
- In Lower-Grade Gliomas, the SPARC Family Exacerbates Prognosis by Influencing Immunity, Stemness, and Metabolism.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvolvement of the SPARC stromal protein family in crucial biological regulatory mechanisms is well-documented. But understanding the consequences of imbalanced SPARC protein activity in lower-grade glioma (LGG) is still emerging.
aimsExamining the clinical significance of SPARC proteins, researchers employed RNA-seq data from diverse patient groups to gain insight. A novel SPARCScore was developed via LASSO regression analysis, leveraging data from the PanCanAtlas and MEXPRESS to shed light on the molecular mechanisms involved. METHODS AND
resultsOur findings indicate that a majority of SPARC family proteins show atypical expression levels, correlating significantly with adverse outcomes in LGG. Our construction of an SPARCscore, indicative of the SPARC family's presence, revealed a direct correlation between a high SPARCscore and worsened tumor prognosis, irrespective of radiotherapy or chemotherapy treatments. The SPARCScore risk groups showed distinct drivers: PIK3CA predominantly influenced the low-risk category, whereas EGFR was a key factor in the high-risk group. High SPARCScore tumors exhibited a mutation profile similar to glioblastoma, marked by reduced methylation and diverse glioma stem cells (GSC). Conversely, the low SPARCScore tumors were characterized by increased methylation and limited GSC variety. Furthermore, the high-SPARCScore group was notable for its pronounced inflammatory and extracellular matrix signatures, along with activated metabolic pathways. These patterns were closely linked to prognosis.
conclusionIn essence, this research highlights the significance of SPARC proteins in LGG, offering insights into promising avenues for targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.